Regeneron Pharmaceuticals Story

<div class='circular--portrait' style='background:#0D8ECF;color: white;font-size:4em;padding-top: 15px;;'>RE</div>
REGN -- USA Stock  

Earning Report: February 6, 2020  

Noise-free headlines and social signals for Regeneron Pharmaceuticals with professional-grade financial sentiment analysis on the corporation that can be used to derive useful patterns or a particular trading strategy for Regeneron Pharmaceuticals. Additionally take a look at Regeneron Pharmaceuticals Hype Analysis, Regeneron Pharmaceuticals Correlation and Regeneron Pharmaceuticals Performance.
Exercise or conversion by Peter Powchik of 16000 shares of Regeneron Pharmaceuticals subject to Rule 16b-3
Filed transaction by Regeneron Pharmaceuticals officer. Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Regeneron Pharmaceuticals insider trading alert for exercise of common stock by Peter Powchik, SVP Clin Devel Reg Affairs, on December 3, 2019. This event was filed by Regeneron Pharmaceuticals with SEC on 2012-12-20. Statement of changes in beneficial ownership - SEC Form 4. Peter Powchik is currently serves as senior vice president - clinical development of Regeneron Pharmaceuticals

Story Momentum

This media report from MacroaxisInsider distributed on December 3, 2019 was a factor to the next trading day price appreciation.The trading delta at closing time against the next closing price was 0.31% . The trading delta at closing time when the story was published against the current closing price is 2.27% .

Similar stores for Regeneron Pharmaceuticals

2 days ago at newssmooth.com 
A Look At Some Cash Alternatives For your Portfolios Regeneron Pharmaceuticals, Inc., - NewsSmooth
news
A Look At Some Cash Alternatives For your Portfolios Regeneron Pharmaceuticals, Inc., NewsSmooth
few days ago at MacroaxisInsider 
Sale by Neil Stahl of 13378 shares of Regeneron Pharmaceuticals
Macroaxis News
Filed transaction by Regeneron Pharmaceuticals officer. General open market or private sale of non-derivative or derivative security
over a week ago at MacroaxisInsider 
Exercise or conversion by Alfred Gilman of 672 shares of Regeneron Pharmaceuticals subject to Rule 16b-3
Macroaxis News
Filed transaction by Regeneron Pharmaceuticals director. Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
over a week ago at MacroaxisInsider 
Exercise or conversion by Joseph Goldstein of 5000 shares of Regeneron Pharmaceuticals subject to Rule 16b-3
Macroaxis News
Filed transaction by Regeneron Pharmaceuticals director. Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
over two weeks ago at MacroaxisInsider 
Exercise or conversion by Douglas McCorkle of 431 shares of Regeneron Pharmaceuticals subject to Rule 16b-3
Macroaxis News
Filed transaction by Regeneron Pharmaceuticals officer. Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
over two weeks ago at MacroaxisInsider 
Acquisition by Bonnie Bassler of 4361 shares of Regeneron Pharmaceuticals subject to Rule 16b-3
Macroaxis News
Filed transaction by Regeneron Pharmaceuticals director. Grant, award or other acquisition pursuant to Rule 16b-3(d)
over two weeks ago at MacroaxisInsider 
Acquisition by Marc TessierLavigne of 4361 shares of Regeneron Pharmaceuticals subject to Rule 16b-3
Macroaxis News
Filed transaction by Regeneron Pharmaceuticals director. Grant, award or other acquisition pursuant to Rule 16b-3(d)
over three weeks ago at MacroaxisInsider 
Payment of 3361 shares by Michael Aberman of Regeneron Pharmaceuticals subject to Rule 16b-3
Macroaxis News
Filed transaction by Regeneron Pharmaceuticals officer. Payment of exercise price or tax liability by delivering or withholding securities
over three weeks ago at MacroaxisInsider 
Exercise or conversion by Alfred Gilman of 5000 shares of Regeneron Pharmaceuticals subject to Rule 16b-3
Macroaxis News
Filed transaction by Regeneron Pharmaceuticals director. Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
over a month ago at MacroaxisInsider 
Acquisition by George Sing of 7830 shares of Regeneron Pharmaceuticals subject to Rule 16b-3
Macroaxis News
Filed transaction by Regeneron Pharmaceuticals director. Grant, award or other acquisition pursuant to Rule 16b-3
over two weeks ago at MacroaxisInsider 
Exercise or conversion by Roberts William of 4562 shares of Regeneron Pharmaceuticals subject to Rule 16b-3
Macroaxis News
Filed transaction by Regeneron Pharmaceuticals officer. Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
over a month ago at MacroaxisInsider 
Exercise or conversion by Joseph Goldstein of 100 shares of Regeneron Pharmaceuticals subject to Rule 16b-3
Macroaxis News
Filed transaction by Regeneron Pharmaceuticals director. Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
over a month ago at MacroaxisInsider 
Sale by Joseph Goldstein of 7500 shares of Regeneron Pharmaceuticals
Macroaxis News
Filed transaction by Regeneron Pharmaceuticals director. General open market or private sale of non-derivative or derivative security

Price to Earning

Price to Earning Comparative Analysis

Regeneron Pharmaceuticals is rated second in price to earning category among related companies. Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investor monitor on a daily basis. Holding a low PE stock is less risky because. When a company's profitability fall, it is likely that earnings will also go down..In other words, if you start from a lower position your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Additionally take a look at Regeneron Pharmaceuticals Hype Analysis, Regeneron Pharmaceuticals Correlation and Regeneron Pharmaceuticals Performance. Please also try Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Company logos by clearbit